Cure Rate Soars For Some AML Patients Receiving High-Dose Drug

October 29, 1998

COLUMBUS, Ohio -- A drug given at levels substantially higher than the standard dose can cure nearly five times as many patients who have a certain type of acute myeloid leukemia (AML), new research shows.

The study revealed that 78 percent of patients with “core binding factor” AML who received the drug cytarabine at high dose were in complete remission five years after treatment (and therefore potentially cured) compared to only 16 percent who received the standard dose.

“It is truly remarkable to achieve a cure rate of over 75 percent in a subgroup of adult leukemia patients; this rate approaches that for some types of childhood leukemia,” said Clara Bloomfield, director of Ohio State University's Comprehensive Cancer Center and William G. Pace III Professor of Cancer Research.

“Because high-dose cytarabine is quite toxic, especially for older people, we want to use it only with those patients who will benefit. These results tell us which patients we can cure, and which ones should receive other therapy.”

The finding is considered particularly strong because the study had followed patients for more than seven years after treatment; most such studies rely on models to project estimates of five-year remission rates.

The study, which was led by Bloomfield, appeared in the September issue of the journal Cancer Research. It involved 285 newly diagnosed AML patients aged 16 and older who were in remission. During the second phase of their treatment, a phase known as “intensification therapy,” the patients were randomly assigned to receive cytarabine at either standard dose (100 milligrams per square meter of body surface), intermediate dose (400 mg/m2), or high-dose (3,000 mg/m2, equivalent to 3 grams of drug/m2).

These groups of patients were then subdivided into three categories according to their cytogenetics; that is, according to the type of chromosome damage present in their malignant cells. Patients showing damage to chromosome 16 or to chromosomes 8 and 21 were assigned to the “core binding factor” (CBF) group; those with no visible chromosome damage were assigned to the “normal” group; and those with other types of chromosome damage were assigned to the “other abnormalities” group.

The outcome of the patients in each chromosome group and at each dose was then examined.

Of the 57 patients in the CBF group, 78 percent of those who received the high drug dose were in complete remission, versus 57 percent receiving the intermediate dose, and 16 percent receiving the standard dose.

Of the 140 patients in the “normal” group, 40 percent of those receiving the high drug dose were in complete remission, compared to 37 percent receiving the intermediate dose, and 20 percent receiving the standard dose.

Last, of the 88 patients in the “other abnormalities” group, 21 percent of those receiving the high drug dose were in complete remission, compared to 13 percent receiving the intermediate dose, and 13 percent receiving the standard dose.

“In the ‘other abnormalities’ group, the dose of cytarabine made no difference,” said Bloomfield. “But in the normal group, using high-dose cytarabine doubled the number of patients cured, and in the CBF group, the high-dose treatment increased the number by nearly five times. Because of these results and this astronomical difference, we now routinely treat CBF patients using high-dose cytarabine.

“The ramifications of these findings are tremendous,” said Bloomfield. “A lot of people are now working to understand why patients with core binding factor leukemias are particularly sensitive to this drug, and that may help us design more rational treatments in general. It’s an excellent example of how clinical findings can spur new laboratory research and perhaps improve cancer treatment in the future.”

The standard treatment for adults with AML occurs in two phases: induction therapy and post-remission therapy. Induction therapy is intended to drive the leukemia into remission (i.e., malignant cells are not visible when a bone marrow sample is examined by microscope).

Post-remission therapy is intended to destroy any remaining leukemic cells; it is essential for long-term remission or cure in AML patients. The most commonly used forms of post-remission therapy are bone marrow transplantation and intensification therapy using high-dose cytarabine.

This study, the first to look at the influence of dose and cytogenetics on cytarabine intensification therapy, was funded by grants from the National Cancer Institute.
-end-
Contact: Clara Bloomfield, (614) 293-7518;
bloomfield-1@medctr.osu.edu
Written by Darrell E. Ward, (614) 292-8456; Ward.25@osu.edu

Ohio State University

Related Acute Myeloid Leukemia Articles from Brightsurf:

Young survivors of acute myeloid leukemia have long-term complications from treatment
Adolescent and young adult (AYA) patients treated for acute myeloid leukemia (AML) have a high risk of developing several long-term health complications after treatment, a study led by UC Davis Comprehensive Cancer Center researchers has found.

Combination therapy improves survival outcomes for patients with acute myeloid leukemia
A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center.

ASH releases new clinical practice guidelines on acute myeloid leukemia in older adults
Today, ASH published new guidelines to help older adults with acute myeloid leukemia (AML) and their health care providers make critical care decisions, including if and how to proceed with cancer treatment and the need for blood transfusions for those in hospice care.

Huntsman Cancer Institute illuminates potential new treatment in acute myeloid leukemia
In a study published in the journal Leukemia, lead author Ami Patel, MD, Huntsman Cancer Institute researcher and assistant professor in the Division of Hematology and Hematologic Malignancies at the University of Utah, showed that factors produced by bone marrow support cells allowed leukemia cells to survive treatment with quizartinib, a type of TKI.

A new nanoconjugate blocks acute myeloid leukemia tumor cells without harming healthy ones
The nanoparticle targets only leukemic cells and therefore would reduce the severe adverse effects of current treatments.

Oncotarget: RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation
The cover for issue 25 of Oncotarget features Figure 8, 'BI-D1870 in combination with vincristine increase metaphase arrest and apoptosis synergistically,' by Chae, et al.

Call for caution for using a CAR-T immunotherapy against acute myeloid leukemia
Researchers from the Josep Carreras Leukaemia Research Institute prove that the preclinical implementation of Acute Myeloid Leukaemia immunotherapy, based on CD123-redirected CAR T-cells, affects hematopoiesis, blood cells production, and reconstitution.

For acute myeloid leukemia, genetic testing is often worth the wait
New tailored therapies offer exciting prospects for treating acute myeloid leukemia (AML), but taking advantage of them may require waiting a week or more for genetic testing before starting treatment, posing a dilemma for doctors and patients facing this deadly and often fast-moving disease.

Discovery in human acute myeloid leukemia could provide novel pathway to new treatments
Researchers at Mount Sinai have discovered that human acute myeloid leukemia (AML) stem cells are dependent on a transcription factor known as RUNX1, potentially providing a new therapeutic target to achieve lasting remissions or even cures for a disease in which medical advances have been limited.

Research revises classification of acute myeloid leukemia & myelodysplastic syndrome
Findings presented as a late-breaking abstract at the American Society of Hematology annual meeting by St.

Read More: Acute Myeloid Leukemia News and Acute Myeloid Leukemia Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.